| Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer K Haratani, H Hayashi, Y Chiba, K Kudo, K Yonesaka, R Kato, H Kaneda, ... JAMA oncology 4 (3), 374-378, 2018 | 873 | 2018 |
| Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment K Haratani, H Hayashi, T Tanaka, H Kaneda, Y Togashi, K Sakai, ... Annals of oncology 28 (7), 1532-1539, 2017 | 296 | 2017 |
| Peripheral blood biomarkers associated with clinical outcome in non–small cell lung cancer patients treated with nivolumab J Tanizaki, K Haratani, H Hayashi, Y Chiba, Y Nakamura, K Yonesaka, ... Journal of thoracic oncology 13 (1), 97-105, 2018 | 214 | 2018 |
| LIS1 and NDEL1 coordinate the plus‐end‐directed transport of cytoplasmic dynein M Yamada, S Toba, Y Yoshida, K Haratani, D Mori, Y Yano, ... The EMBO journal 27 (19), 2471-2483, 2008 | 210 | 2008 |
| Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer K Isomoto, K Haratani, H Hayashi, S Shimizu, S Tomida, T Niwa, ... Clinical Cancer Research 26 (8), 2037-2046, 2020 | 181 | 2020 |
| Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer H Kawakami, J Tanizaki, K Tanaka, K Haratani, H Hayashi, M Takeda, ... Investigational New Drugs 35, 529-536, 2017 | 154 | 2017 |
| B7-H3 negatively modulates CTL-mediated cancer immunity K Yonesaka, K Haratani, S Takamura, H Sakai, R Kato, N Takegawa, ... Clinical Cancer Research 24 (11), 2653-2664, 2018 | 137 | 2018 |
| [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification N Takegawa, J Tsurutani, H Kawakami, K Yonesaka, R Kato, K Haratani, ... International Journal of Cancer 145 (12), 3414-3424, 2019 | 84 | 2019 |
| An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC K Yonesaka, N Takegawa, S Watanabe, K Haratani, H Kawakami, ... Oncogene 38 (9), 1398-1409, 2019 | 84 | 2019 |
| Clinical application of the FoundationOne CDx assay to therapeutic decision‐making for patients with advanced solid tumors M Takeda, T Takahama, K Sakai, S Shimizu, S Watanabe, H Kawakami, ... The oncologist 26 (4), e588-e596, 2021 | 74 | 2021 |
| Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer S Watanabe, K Yonesaka, J Tanizaki, Y Nonagase, N Takegawa, ... Cancer medicine 8 (3), 1258-1268, 2019 | 69 | 2019 |
| U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation K Haratani, K Yonesaka, S Takamura, O Maenishi, R Kato, N Takegawa, ... The Journal of clinical investigation 130 (1), 374-388, 2020 | 59 | 2020 |
| KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms S Suzuki, K Yonesaka, T Teramura, T Takehara, R Kato, H Sakai, ... Clinical Cancer Research 27 (20), 5697-5707, 2021 | 57 | 2021 |
| A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors … H Hayashi, S Sugawara, Y Fukuda, D Fujimoto, S Miura, K Ota, Y Ozawa, ... Clinical Cancer Research 28 (5), 893-902, 2022 | 54 | 2022 |
| HER3 augmentation via blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non–small cell lung cancer K Yonesaka, J Tanizaki, O Maenishi, K Haratani, H Kawakami, K Tanaka, ... Clinical Cancer Research 28 (2), 390-403, 2022 | 50 | 2022 |
| Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts R Kato, K Haratani, H Hayashi, K Sakai, H Sakai, H Kawakami, K Tanaka, ... British journal of cancer 124 (5), 914-924, 2021 | 50 | 2021 |
| Real‐world data on NGS using the Oncomine DxTT for detecting genetic alterations in non‐small‐cell lung cancer: WJOG13019L S Sakata, K Otsubo, H Yoshida, K Ito, A Nakamura, S Teraoka, ... Cancer Science 113 (1), 221-228, 2022 | 44 | 2022 |
| Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class i expression via the extracellular signal‐regulated kinase … S Watanabe, H Hayashi, K Haratani, S Shimizu, J Tanizaki, K Sakai, ... Cancer Science 110 (1), 52-60, 2019 | 44 | 2019 |
| MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer S Kitajima, T Tani, BF Springer, M Campisi, T Osaki, K Haratani, M Chen, ... Cancer Cell 40 (10), 1128-1144. e8, 2022 | 37 | 2022 |
| Clinical and immune profiling for cancer of unknown primary site K Haratani, H Hayashi, T Takahama, Y Nakamura, S Tomida, T Yoshida, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 34 | 2019 |
